NO20055708L - Syntetisk gen som koder for humant karsinembryonalt antigen og anvendelser derav - Google Patents

Syntetisk gen som koder for humant karsinembryonalt antigen og anvendelser derav

Info

Publication number
NO20055708L
NO20055708L NO20055708A NO20055708A NO20055708L NO 20055708 L NO20055708 L NO 20055708L NO 20055708 A NO20055708 A NO 20055708A NO 20055708 A NO20055708 A NO 20055708A NO 20055708 L NO20055708 L NO 20055708L
Authority
NO
Norway
Prior art keywords
cea
gene encoding
embryonic antigen
encoding human
synthetic gene
Prior art date
Application number
NO20055708A
Other languages
English (en)
Norwegian (no)
Other versions
NO20055708D0 (no
Inventor
Nicola La Monica
Armin Lahm
Carmela Mennuni
Rocco Savino
Original Assignee
Angeletti P Ist Richerche Bio
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Angeletti P Ist Richerche Bio filed Critical Angeletti P Ist Richerche Bio
Publication of NO20055708D0 publication Critical patent/NO20055708D0/no
Publication of NO20055708L publication Critical patent/NO20055708L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/665—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin
    • C07K14/70—Enkephalins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/022—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from an adenovirus

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
NO20055708A 2003-05-05 2005-12-02 Syntetisk gen som koder for humant karsinembryonalt antigen og anvendelser derav NO20055708L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US46797103P 2003-05-05 2003-05-05
US54361204P 2004-02-11 2004-02-11
PCT/EP2004/004802 WO2004099247A2 (en) 2003-05-05 2004-05-03 Synthetic gene encoding human carcinoembryonic antigen and uses thereof

Publications (2)

Publication Number Publication Date
NO20055708D0 NO20055708D0 (no) 2005-12-02
NO20055708L true NO20055708L (no) 2006-02-06

Family

ID=33436748

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20055708A NO20055708L (no) 2003-05-05 2005-12-02 Syntetisk gen som koder for humant karsinembryonalt antigen og anvendelser derav

Country Status (12)

Country Link
US (1) US20070104685A1 (is)
EP (1) EP1622937A2 (is)
JP (1) JP2007523610A (is)
KR (1) KR20060003903A (is)
CN (1) CN1784424A (is)
AU (1) AU2004235943A1 (is)
CA (1) CA2523720A1 (is)
IS (1) IS8053A (is)
NO (1) NO20055708L (is)
NZ (1) NZ543922A (is)
RU (1) RU2005137697A (is)
WO (1) WO2004099247A2 (is)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060286114A1 (en) * 2003-08-22 2006-12-21 Luigi Aurisicchio Synthetic gene encoding rhesus monkey carcinoembryonic antigen and uses thereof
ATE555127T1 (de) * 2004-02-11 2012-05-15 Angeletti P Ist Richerche Bio Fusionsproteine des karzinomembryonalen antigens und deren verwendungen
JP4881623B2 (ja) 2006-01-27 2012-02-22 シスメックス株式会社 Ｃｅａ核酸増幅用プライマー、プライマーセット、及びがんの診断支援方法
US20090304725A1 (en) * 2006-02-06 2009-12-10 Medizinische Universitat Wien Vaccine and Antigen Mimotopes Against Cancerous Diseases Associated with the Carcinoembryonic Antigen CEA
ES2725450T3 (es) 2007-07-02 2019-09-24 Etubics Corp Métodos y composiciones para la producción de un vector adenoviral para su uso en vacunaciones múltiples
NZ582823A (en) * 2007-07-27 2012-04-27 Immatics Biotechnologies Gmbh Composition of tumour-associated peptides and related anti-cancer vaccine
WO2009117656A2 (en) * 2008-03-21 2009-09-24 Vectorlogics,Inc. Capsid-incorporated antigen for novel adenovirus vaccine
KR101815322B1 (ko) * 2010-01-12 2018-01-05 서울대학교산학협력단 항암 펩타이드 서열
US9605276B2 (en) * 2012-08-24 2017-03-28 Etubics Corporation Replication defective adenovirus vector in vaccination
AU2016205215B2 (en) 2015-01-09 2021-03-11 Etubics Corporation Methods and compositions for combination immunotherapy
US10695417B2 (en) 2015-01-09 2020-06-30 Etubics Corporation Human adenovirus serotype 5 vectors containing E1 and E2B deletions encoding the ebola virus glycoprotein
US11149087B2 (en) 2015-04-20 2021-10-19 Etubics Corporation Methods and compositions for combination immunotherapy
EP3864169A4 (en) * 2018-10-12 2022-07-06 Children's Hospital Medical Center MODULAR EXPRESSION SYSTEMS FOR GENE EXPRESSION AND METHODS FOR THEIR USE

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5795737A (en) * 1994-09-19 1998-08-18 The General Hospital Corporation High level expression of proteins
DE10055545A1 (de) * 2000-11-09 2002-07-25 Deutsches Krebsforsch Für Expression in Eukaryonten optimierte HPV 16-L1 und HPV 16-L2 kodierende DNA Sequenzen

Also Published As

Publication number Publication date
IS8053A (is) 2005-09-29
AU2004235943A1 (en) 2004-11-18
RU2005137697A (ru) 2006-05-10
WO2004099247A2 (en) 2004-11-18
CA2523720A1 (en) 2004-11-18
EP1622937A2 (en) 2006-02-08
CN1784424A (zh) 2006-06-07
US20070104685A1 (en) 2007-05-10
NO20055708D0 (no) 2005-12-02
NZ543922A (en) 2008-05-30
KR20060003903A (ko) 2006-01-11
WO2004099247A3 (en) 2005-02-24
JP2007523610A (ja) 2007-08-23

Similar Documents

Publication Publication Date Title
ATE474048T1 (de) Her2/neu fusionsproteine
NO20060813L (no) Syntetisk gen som koder for human epidermalvekstfaktor 2/NEU og andvendelser derav
JP2023123609A (ja) 個別化ワクチン
EP1716173B8 (en) Carcinoembryonic antigen fusion protein and uses thereof
DE602004027902D1 (de) Dna-vakzine gegen tumorwachstum und anwendungsverfahren dafür
MX2009003873A (es) Proteina de fusion de transcriptasa inversa de telomerasa, nucleotidos que la codifican y usos de la misma.
HUP0002095A2 (hu) Vegyületek prosztatarák immunterápiás kezelésére és alkalmazásuk
HUP0302532A2 (hu) Petefészekrák terápiájában és diagnosztizálásában alkalmazható készítmények és eljárások
PH12019502847A1 (en) Novel t cell receptors and immune therapy using the same
NZ746916A (en) Construction of oncolytic herpes simplex viruses (ohsv) obligate vector and constructs for cancer therapy
DE69839970D1 (de) Methoden zu herstellung von genbanken
WO2002012341A3 (en) Her-2/neu fusion proteins
CY1116413T1 (el) Καινοφανη πληρως-ανθρωπινα μονοκλωνικα αντισωματα anti-vap-1
Kim et al. Poxviral vectors for cancer immunotherapy
Senzer et al. A review of contusugene ladenovec (Advexin) p53 therapy
WO2011119925A3 (en) Synthetic herpes simplex viruses for treatment of cancers
WO2004099247A3 (en) Synthetic gene encoding human carcinoembryonic antigen and uses thereof
DK1536006T3 (da) Cancerantigener og anvendelse deraf
Kang et al. Targeted coating with antigenic peptide renders tumor cells susceptible to CD8+ T cell-mediated killing
Nelson et al. Venezuelan equine encephalitis replicon immunization overcomes intrinsic tolerance and elicits effective anti-tumor immunity to the ‘self’tumor-associated antigen, neu in a rat mammary tumor model
EP1934246B8 (en) Matrix metalloproteinase 11 vaccine
NO20055209L (no) Peptabody for cancerbehandling
WO2003044161A3 (en) Gene amplification and overexpression in cancer
MX2021013822A (es) Virus de fiebre amarilla atenuado y usos del mismo para el tratamiento de cancer.
ATE331796T1 (de) Rhesus-karzinoembryonales antigen, dieses codierende nukleotide und verwendungen davon

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application